As Biotechnology companies, Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) and Magenta Therapeutics Inc. (NASDAQ:MGTA) are our subject to contrast. And more specifically their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.

Valuation and Earnings

Table 1 highlights Brainstorm Cell Therapeutics Inc. and Magenta Therapeutics Inc.s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 shows us Brainstorm Cell Therapeutics Inc. and Magenta Therapeutics Inc.s net margins, return on equity and return on assets.

Liquidity

The Current Ratio of Brainstorm Cell Therapeutics Inc. is 1 while its Quick Ratio stands at 1. The Current Ratio of rival Magenta Therapeutics Inc. is 17.1 and its Quick Ratio is has 17.1. Magenta Therapeutics Inc. is better equipped to clear short and long-term obligations than Brainstorm Cell Therapeutics Inc.

Analyst Recommendations

In next table is given Brainstorm Cell Therapeutics Inc. and Magenta Therapeutics Inc.s ratings and recommendations.

Brainstorm Cell Therapeutics Inc. has a 126.70% upside potential and an average price target of $9.

Institutional & Insider Ownership

Institutional investors owned 11.4% of Brainstorm Cell Therapeutics Inc. shares and 85.4% of Magenta Therapeutics Inc. shares. 0.6% are Brainstorm Cell Therapeutics Inc.s share owned by insiders. Comparatively, 2.2% are Magenta Therapeutics Inc.s share owned by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Brainstorm Cell Therapeutics Inc.s stock price has smaller growth than Magenta Therapeutics Inc.

Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders that include amyotrophic lateral sclerosis, multiple sclerosis, Parkinsons disease, and others. The company holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. Its NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in Hackensack, New Jersey.

Magenta Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing medicines to bring the curative power of bone marrow transplant to patients. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an ADC program to prevent acute graft and host diseases. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. Magenta Therapeutics, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Read this article:
Contrasting of Brainstorm Cell Therapeutics Inc. (BCLI) and Magenta Therapeutics Inc. (NASDAQ:MGTA) - MS Wkly